After medical and PhD degrees, and a fellowship in pathology, my career has involved academic positions in Australia and the US, as well as several years in biotech. Throughout, I have been interested in the mechanisms of transplant rejection and autoimmunity, and how these processes can be usefully regulated. This search for therapeutic strategies to enhance outcomes post-transplant led to studies of the anti-inflammatory properties of anticoagulant molecules, ways to improve the outcomes of xenotransplantation via induction of “protective” genes, and back to allotransplantation and studies of novel costimulation molecules, and then chemokine and their receptors. For the past decade, my work has especially focused on therapeutic and discovery efforts in the area of Foxp3+ T-regulatory (Treg) cell biology.
Professor of Pathology and Laboratory Medicine, University of Pennsylvania
Chief of the Division of Transplant Immunology, Children’s Hospital of Philadelphia (CHOP)
MB.BS., Monash University, Australia, 1977
PhD, Monash University, Australia, 1983
Post-doc, Brigham and Women’s Hospital and Harvard Medical School, Boston 1984-86
Asst. Prof., Depts. Medicine, Pathology and Surgery, University of Connecticut, 1986-89
Senior Lecturer, Pathology and Immunology, Monash Medical School, Australia, 1990-1994
Fellowship of the Royal College of Pathologists of Australasia, 1989
Assoc. Prof., Dept. of Pathology, Harvard Medical School, 1994-1999
Senior Director, Experimental Therapeutics, LeukoSite, Inc., Cambridge, MA, 1997-99
Senior Director of Transplantation and Senior Director of Molecular Pharmacology, Millennium Pharmaceuticals, Inc., Cambridge, MA, 1999-2001
Investigator, Stokes Research Institute and Biesecker Pediatric Liver Center, CHOP, 2001-
Professor of Pathology and Laboratory Medicine (with tenure), University of Pennsylvania, 2002-
